Study: Treatment of Covid-19 symptoms with traditional Chinese medicine

Aktualisiert:

Von Natur.wiki Autoren-Team

Die vorliegende Studie untersucht die Auswirkungen von Shengmai Yin auf die Lungen- und Herzfunktion bei rekonvaleszenten Patienten mit kardiopulmonalen Symptomen der Coronavirus-Erkrankung 2019 (Covid-19). Es handelt sich um eine randomisierte, doppelblinde, multizentrische Kontrollstudie mit 200 Teilnehmern. Das Hauptziel der Studie war die Bewertung der Sicherheit und Wirksamkeit von Shengmai Yin bei der Linderung von kardiopulmonalen Symptomen. Die Studie ergab, dass Shengmai Yin wirksam war, um Brustbeschwerden zu lindern, aber keine signifikanten Verbesserungen bei Atemnot, Hidrosis, Herzklopfen und trockenem Husten zeigte. Es wurden keine größeren Nebenwirkungen festgestellt. Die Ergebnisse deuten darauf hin, dass Shengmai Yin eine einfache und vorteilhafte Maßnahme zur …
The present study examines the effects of Shengmai Yin on the lung and heart function in convalescent patients with cardiopulmonary symptoms of coronavirus disease 2019 (COVID-19). It is a randomized, double -blind, multicenter control study with 200 participants. The main goal of the study was the evaluation of the security and effectiveness of Shengmai Yin in relieving cardiopulmonary symptoms. The study showed that Shengmai Yin was effective to relieve breast complaints, but showed no significant improvements in shortness of breath, hididosis, palpitations and dry cough. No major side effects were found. The results indicate that Shengmai Yin is a simple and advantageous measure for ... (Symbolbild/natur.wiki)

The present study examines the effects of Shengmai Yin on the lung and heart function in convalescent patients with cardiopulmonary symptoms of coronavirus disease 2019 (COVID-19). It is a randomized, double -blind, multicenter control study with 200 participants. The main goal of the study was the evaluation of the security and effectiveness of Shengmai Yin in relieving cardiopulmonary symptoms. The study showed that Shengmai Yin was effective to relieve breast complaints, but showed no significant improvements in shortness of breath, hididosis, palpitations and dry cough. No major side effects were found. The results indicate that Shengmai Yin can be a simple and advantageous measure to improve the quality of life of convalescent covid 19 patients. However, further studies are required to confirm the effectiveness of the formula in a clinical environment and to determine the exact dosage and administration methods.

Details of the study:

Reference

XUedong on, Lina M, Ping X, et al. Effects of Shengmai Yin ( 生脉 ) On the lung and heart function in convalescent patients with cardiopulmonary symptoms of coronavirus disease 2019: a randomized, double-blind, multicenter control study. j tradit Chin med . 2023; 43 (1): 140-145.

Study goal

Assessment of the security and effectiveness of Shengmai Yin using a visual analog scale (VAS) for cardiopulmonary symptoms in reconvalescent patients with covid-19

Key to take away

The Shengmai Yin formula can be a simple and advantageous measure to improve the quality of life of convalescent patients with covid-19, especially when it comes to alleviating the symptoms of breast problems of the patient.

Design

randomized, double blind, multicenter, controlled study

participant

In the study, 200 convalescent Covid-19 patients with cardiopulmonary symptoms in three medical centers: 100 patients in the test group (men = 41; women = 59) and 100 patients in the control group (men = 31; women = 69). 192 patients completed the study (98 in the test group and 94 in the control group).

inclusion criteria: no fever for at least 72 hours, clinical remission of respiratory problems, significant improvement in both lungs in the chest computer tomography (CT) and 2 negative throat smears for SARS-COV-2-RNA at a distance of at least 24 hours. Additional criteria: (a) 2 to 3 symptoms or at least 1 symptom with a vas score larger than 4; (b) 2 to 4 weeks since dismissal from the hospital; (c) at the age of 18 to 70; and (d) signed declaration of consent.

exclusion criteria: (a) patients with difficulties taking oral drugs due to underlying diseases; (b) Basic diseases that affect survival (uncontrolled heart, lung, kidney, digestive, hematological, neuropsychiatric or immunological diseases; metabolic diseases; malignant diseases; serious malnutrition); (c) Allergic predisposition, allergies against the drugs contained in the treatment plan; (d) pregnancy or breastfeeding; (e) mental illness, changing state of mind, communication deficiencies or lack of self -confidence and (f) participation in other clinical studies.

Intervention

The patients took 10 ml Shengmai Yin (Tong Ren Tang Technologies Co.) for 2 weeks.

studied study parameters

The researchers assessed the following symptoms based on the VAS, which were rated after 0, 1 and 2 weeks with 0 to 10:

  • shortness of breath,

  • HIDROSIS,

  • breast complaints,

  • papers and

  • dry cough.

Primary endpoint evaluated

as effective, the researchers defined a reduction in the VAS by 30 % or more. As curative, they defined a reduction of the vas to 0.

most important findings

The Shengmai Yin treatment was effective in relieving breast complaints ( p = 0.008). After 2 weeks there was no significant difference in shortness of breath, hididosis, palpitations and dry cough.

Transparency

The investigators did not find any disclosures or sources of study.

Effects and restrictions for practice

Shengmai San is a popular formula of traditional Chinese medicine (TCM) that contains three ingredients: radix ginseng , radix ophiopogonis and fructus schisandrae . It can be administered as a liquid (Shengmai Yin, which was used in this study), Shengmai capsule or granulate or through a modern application of the formula as intravenous infusion (used in China). It is a Qi and Yin tonic and is often given patients in the recovery phase if they are weakened by a serious illness to get back to strength. Shengmai means "restore or generate pulse" and is intended to improve the strength and quality of the pulse of the patient, which reflects a general improvement in their condition and vitality.

Shengmai formulas have shown considerable advantages in cardiovascular and respiratory diseases and were discussed in detail in the literature. 1,2 Some of its effects include positive advantages in heart failure, 3 Dilatative Cardiomyopathy, 4 and improves breathing function in chronically obstructive lung disease (COPD). 5 The diverse research behind Shengmai Yin makes it a logical choice for the treatment of Covid-19 patients, which Among other things, have a significant burden on both cardiovascular and respiratory functions.

A higher dosage could have improved the result.

The study lasted two weeks and analyzed the reactions of the patients in five areas: shortness of breath, hydrosis, breast problems, palpitations and dry cough. Only breast complaints showed a statistically significant improvement compared to the self-reported VAS score. No major side effects were found. Several reasons can be responsible for the fact that only one of five symptoms improved, including: dosage, type of administration, study time, comorbidities and surveillance parameters.

A higher dosage could have improved the result. The patients in this study received 10 ml of the formula three times a day over a period of 2 weeks, which corresponds to a total dose of 30 ml per day. In another small study with patients with dilatative cardiomyopathy, a 20 ml formula was used twice a day for a total dose of 40 ml per day. This study resulted in increased stress tolerance and improved left -wing ventricular contractility in patient population.

also the type of administration and combination with other therapies can play a role for the result. In the past, a study time of only two weeks was carried out, but these studies used an intravenous preparation of the formula, which avoided a ridge-pass effect in the body. Oral therapies usually need more time to achieve the destinations.

In a small study with 20 patients with COPD, those who were treated with an intravenous preparation of the Shengmai formula for a total of 14 days showed an improved breathing function. 5 We clinically seen how different the severity of Covid-19 is with different people. While the study excluded certain life -threatening impending conditions that impair survival, many factors are not taken into account in this study that can play a role when the illness and recovery progresses. Some of these factors are related to the virus itself, for example with the severity of infections caused by various tribes of SARS-COV-2 infections. Some factors are related to host and environmental factors: lifestyle, nutrition, activity level, habits, genetics, status of body composition, vitamin D status, underlying chronic diseases, co-factors and environmental factors such as climate and air pollution as well as cultural factors and socio-economic factors.

Overall, this study supports a short-term, secure use of Shangmai Yin as a quality of life intervention in convalescent covid 19 patients. Other studies that use quantifiable clinical instruments, such as: B. laboratory and imaging studies for measuring the cardiovascular, respiratory and immune response would be helpful in order to demonstrate the further effectiveness of the formula in a clinical environment.

  1. ouyang y, tang, l, hu s, et al. Prescription of compounds derived from Shengmai San: an overview of chemical components, pharmacokinetic studies, quality control and pharmacological properties. phytomedicine . 2022; 107: 154433

  2. Huang X, Duan X, Wang K, Wu J, Zhang X. Shengmai injection as an additional therapy for the treatment of chronically obstructive lung diseases: a systematic review and meta-analysis. Supplement Ther Med . 2019; 43: 140-147.

  3. Ding Hy, Wang BH, XU Q.

  4. Jian J, Jing F, Decheng L. Effects of Shengmai Yin on left ventricular performance and stress tolerance in patients with dilatative cardiomyopathy. Chin J Cardiol . 1988; 16 (1): 65-67, 125.

  5. Fang Z, Jiang H, Wang L. Therapeutic effects of the Shengmai injection on the breathing function in chronically obstructive lung disease. Chin J Integ Med . 2000; 6 (2): 101-103.

  6. hu j, zhang w, xie ym, wang lx, never XL, zhang yl. Meta-analysis of Shenmai injection treatment in acute myocardial infarction. ZhongGuo Zhong Yao Za Zhi . 2012; 37 (18): 2760-2767.

  7. samadizadeh s, Masoudi M, Rastegar M, Salimi v, Shahbaz MB, Tahamtan A. Covid-19: Why does the seriousness of the disease to person varies to person? Respir Med . 2021; 180: 106356.